Pharma Pulse 7/30/25: Growing Excitement Around Biomarkers in Clinical Trials; Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment

Growing Excitement Around Biomarkers in Clinical Trials

In an interview with Applied Clinical Trials, Michael Miller, chief operating officer of Quanterix, highlighted growing excitement around biomarker integration in clinical trials, particularly for their role in improving efficiency, patient selection, and outcomes—especially in neurology and oncology.

Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment

In an interview with Pharmaceutical Executive, Neha Anand, Analyst at Citeline, explained how AbbVie’s newly approved antibody drug conjugate, Emrelis, could position the company as a serious competitor in MET-high non-small cell lung cancer by targeting a niche biomarker, signaling FDA support for precision oncology, and potentially reshaping AbbVie’s role in the solid tumor treatment landscape.

EHA 2025: Golcadomide Shows Deep Responses in High-Risk Follicular Lymphoma

Updated Phase I/II data presented at EHA 2025 show that golcadomide, an oral CELMoD, achieved a 63% complete response rate in high-risk relapsed/refractory follicular lymphoma when combined with rituximab, with expert insights highlighting its potent, targeted mechanism, outpatient-friendly dosing, and potential to rival existing chemo-free regimens.

Study Shows DNA Regulatory Switch Prompts Stem Cells to Give Rise to Blood

A new study led by Stephen Nimer reveals that TAF1 acts as a molecular switch guiding blood stem cells to mature into different blood cell types without affecting their self-renewal, uncovering a potential therapeutic target for blood cancers that may spare normal hematopoiesis.

Pause and Reset: More Than Just 3 Words

Reflecting on lessons from the pandemic and beyond, this essay explores how the simple act of pausing—whether in speech, breath, daily routines, or clinical care—can enhance clarity, reduce stress, and support emotional and psychological healing across personal and professional settings.